Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01462773 · ClinicalTrials.gov registry record · Phase 1

Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma

A Phase 1 study of Melanoma, sponsored by Ohio State University Comprehensive Cancer Center.

Completed
Registry status
Phase 1
Development phase
16
Enrollment target
1
Study location

NCT01462773 is a Phase 1 study of Melanoma that has completed, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 16 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01462773, a Phase 1 study of Melanoma, has completed, sponsored by Ohio State University Comprehensive Cancer Center.

COMPLETED
Registry status
Phase 1
Development phase
16 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine the safety, tolerability and dose limiting toxicities (DLTs) of VELCADE when administered in combination with interferon-alpha-2b (IFN-α-2b) to patients with metastatic malignant melanoma.

Conditions Studied

Melanoma

Interventions

  • DRUG Bortezomib
  • DRUG Interferon Alfa-2b

Study Locations (1)

Ohio

  • Ohio State University - Columbus

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2006-01
Est. Completion 2013-04
Phase Phase 1

Sponsor

Ohio State University Comprehensive Cancer Center

341 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01462773

The ClinicalTrials.gov registry entry for NCT01462773 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (98% lower). The listed sponsor is Ohio State University Comprehensive Cancer Center, which has 341 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 2 interventions - of which Bortezomib is the first listed.

NCT01462773 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT01462773 about?

NCT01462773 is a clinical study titled "Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma". The purpose of this study is to determine the safety, tolerability and dose limiting toxicities (DLTs) of VELCADE when administered in combination with interferon-alpha-2b (IFN-α-2b) to patients with metastatic malignant melanoma.

What is the current status of trial NCT01462773?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2006-01. Estimated completion is 2013-04.

What conditions does trial NCT01462773 study?

This clinical trial studies the following conditions: Melanoma.

What interventions are being tested in trial NCT01462773?

The interventions under investigation include: Bortezomib (DRUG), Interferon Alfa-2b (DRUG).

Who is sponsoring clinical trial NCT01462773?

This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01462773 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Melanoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Melanoma

All registered trials for this condition

Ohio

All trials with a study site in Ohio

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.